Why Gilead (Nasdaq: GILD) Is Still A Biotech Stock to Buy
April 16, 2015 at 12:17 PM EDT
Gilead Sciences Inc. (Nasdaq: GILD) is facing criticism again this week for its highly priced Hepatitis C drug Sovaldi. The drug costs $1,000 per pill. According to The Wall Street Journal , many states have restricted access to the drug, leaving some patients unable to afford the treatment. But despite the criticism, Gilead (Nasdaq: GILD) stock remains one of the best biotech stocks to buy today. Here's why... Tags: $GILD , Best Biotech Stocks , biotech stocks , biotech stocks to buy , GILD stock , Gilead stock , Nasdaq: GILD , Stocks to Buy To get full access to all Money Morning content, click here About Money Morning: Money Morning gives you access to a team of ten market experts with more than 250 years of combined investing experience – for free . Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors. Disclaimer: © 2015 Money Morning and Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201. The post Why Gilead (Nasdaq: GILD) Is Still A Biotech Stock to Buy appeared first on Money Morning - We Make Investing Profitable .